MA54880A - Compositions et procédés de traitement de troubles neurocognitifs - Google Patents

Compositions et procédés de traitement de troubles neurocognitifs

Info

Publication number
MA54880A
MA54880A MA054880A MA54880A MA54880A MA 54880 A MA54880 A MA 54880A MA 054880 A MA054880 A MA 054880A MA 54880 A MA54880 A MA 54880A MA 54880 A MA54880 A MA 54880A
Authority
MA
Morocco
Prior art keywords
compositions
methods
neurocognitive disorders
treating neurocognitive
treating
Prior art date
Application number
MA054880A
Other languages
English (en)
Inventor
Oliver Cooper
Mark Deandrade
Chris Mason
Robert Plasschaert
Til Nico Peter Van
Original Assignee
Avrobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avrobio Inc filed Critical Avrobio Inc
Publication of MA54880A publication Critical patent/MA54880A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
MA054880A 2019-02-01 2020-01-31 Compositions et procédés de traitement de troubles neurocognitifs MA54880A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962800177P 2019-02-01 2019-02-01

Publications (1)

Publication Number Publication Date
MA54880A true MA54880A (fr) 2021-12-08

Family

ID=71840202

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054880A MA54880A (fr) 2019-02-01 2020-01-31 Compositions et procédés de traitement de troubles neurocognitifs

Country Status (7)

Country Link
US (1) US20220133808A1 (fr)
EP (1) EP3917620A4 (fr)
JP (2) JP2022523514A (fr)
CA (1) CA3127808A1 (fr)
IL (1) IL285270A (fr)
MA (1) MA54880A (fr)
WO (1) WO2020160468A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019152706A1 (fr) 2018-01-31 2019-08-08 Alector Llc Anticorps anti-ms4a6a et leurs procédés d'utilisation
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
WO2021067611A2 (fr) * 2019-10-01 2021-04-08 Children's Medical Center Corporation Compositions et méthodes de traitement de la maladie d'alzheimer
EP4146797A1 (fr) * 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Traitement pour les maladies neurodégénératives
WO2022006105A2 (fr) * 2020-07-02 2022-01-06 Avrobio, Inc. Compositions et méthodes pour traiter des troubles neurocognitifs
US20230265456A1 (en) * 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
US20220127347A1 (en) * 2020-10-26 2022-04-28 The Regents Of The University Of California Inhibition of Tau Propagation
CA3214688A1 (fr) 2021-04-08 2022-10-13 Andrzej KROLEWSKI Procedes de diagnostic et de prediction de declin renal
WO2023156807A2 (fr) * 2021-09-27 2023-08-24 Curelab Oncology, Inc. Prévention et traitement de maladies par modulation de l'activité de cellules souches mésenchymateuses avec un vecteur codant pour p62 (sqstm1) et formulations pharmaceutiques contenant des protéines p62 (sqstm1)
WO2023108290A1 (fr) * 2021-12-15 2023-06-22 The Governing Council Of The University Of Toronto Inhibiteurs peptidiques et procédés d'inhibition de l'agrégation de protéines dans les neurones et les maladies neurodégénératives
WO2024178386A1 (fr) * 2023-02-24 2024-08-29 Aarhus Universitet Méthodes de traitement des maladies du trafic endosomal
AU2024344891A1 (en) * 2023-09-22 2026-04-16 The Board Of Regents Of The University Of Texas System Novel secretory signal peptides and uses thereof
CN117736321A (zh) * 2023-12-20 2024-03-22 中国人民解放军空军军医大学 一种乙酰化修饰的特异性抗体及其应用
WO2025186293A1 (fr) * 2024-03-06 2025-09-12 Institut National de la Santé et de la Recherche Médicale Mutants de chmp2b destinés à être utilisés pour traiter une infection
KR20260001543A (ko) * 2024-06-25 2026-01-06 연세대학교 산학협력단 바이러스 벡터를 포함한 난청 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002911A2 (fr) * 1998-07-10 2000-01-20 Curagen Corporation INTERACTION DE PRECURSEUR DE LA PROTEINE BETA-AMYLOIDE HUMAINE (β-APP) ET DE PROTEINE HUMAINE DU TYPE LON-PROTEASE (HsLON)
EP1461087A1 (fr) * 2001-12-06 2004-09-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation des cellules hematopoietiques cd34+ dans le traitement des troubles snc
US20130102538A1 (en) * 2010-05-05 2013-04-25 Amicus Therapeutics, Inc. Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
JP2016537995A (ja) * 2013-11-05 2016-12-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新しいアルツハイマー病動物モデル
WO2017147509A1 (fr) * 2016-02-25 2017-08-31 Marco Colonna Compositions comprenant de la trem2 et leurs procédés d'utilisation
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
KR102040364B1 (ko) * 2017-05-26 2019-11-05 가천대학교 산학협력단 알츠하이머병 관련 ３０개 유전자를 이용한 유전적 진단방법
BR112020001060A2 (pt) * 2017-07-27 2020-07-14 Novartis Ag variantes de trem2 resistentes a shedase

Also Published As

Publication number Publication date
EP3917620A1 (fr) 2021-12-08
WO2020160468A1 (fr) 2020-08-06
EP3917620A4 (fr) 2023-02-08
JP2025062601A (ja) 2025-04-14
CA3127808A1 (fr) 2020-08-06
US20220133808A1 (en) 2022-05-05
JP2022523514A (ja) 2022-04-25
IL285270A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MA54880A (fr) Compositions et procédés de traitement de troubles neurocognitifs
EP3917539A4 (fr) Compositions et procédés de traitement des troubles neurocognitifs
EP3890748A4 (fr) Compositions et procédés de traitement de troubles hépatiques
EP3973047A4 (fr) Procédés et compositions pour le traitement de troubles hépatiques
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
EP3368560A4 (fr) Variants du facteur viii à cpg réduit, compositions, procédés et utilisations pour le traitement d'affections hémostatiques
EP3781214A4 (fr) Compositions et procédés de traitement de l'amyotrophie spinale
EP3474879A4 (fr) Compositions et procédés de traitement d'un mélanome
EP3496739A4 (fr) Compositions et procédés de traitement de l'hypertension pulmonaire
MA55087A (fr) Compositions et procédés de traitement de laminopathies
IL289173A (en) Preparations and methods for the treatment of central nervous system disorders
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP3969597A4 (fr) Compositions et procédés pour le traitement de maladies médiées par l'atpase
EP3684373A4 (fr) Compositions et procédés pour traiter et améliorer des affections respiratoires et une inflammation de la muqueuse
EP3331527A4 (fr) Procédés de traitement de troubles du développement à l'aide de pipradrol
EP3761970A4 (fr) Compositions et procédés pour le traitement de maladies neurologiques
IL289172A (en) Preparations and methods for the treatment of central nervous system disorders
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
EP3873525A4 (fr) Compositions et procédés de traitement d'une lésion cérébrale
EP3955937A4 (fr) Composés et procédés pour le traitement de troubles oculaires
EP3969456A4 (fr) Procédés de traitement d'un trouble médié par mk2
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
EP3801590A4 (fr) Compositions et procédés de traitement du psoriasis